Literature DB >> 33557396

HIV-1 Tat Activates Akt/mTORC1 Pathway and AICDA Expression by Downregulating Its Transcriptional Inhibitors in B Cells.

Burkitkan Akbay1,2, Diego Germini1, Amangeldy K Bissenbaev2,3, Yana R Musinova4,5, Evgeny V Sheval5, Yegor Vassetzky1,4, Svetlana Dokudovskaya1.   

Abstract

HIV-1 infects T cells, but the most frequent AIDS-related lymphomas are of B-cell origin. Molecular mechanisms of HIV-1-induced oncogenic transformation of B cells remain largely unknown. HIV-1 Tat protein may participate in this process by penetrating and regulating gene expression in B cells. Both immune and cancer cells can reprogram communications between extracellular signals and intracellular signaling pathways via the Akt/mTORC1 pathway, which plays a key role in the cellular response to various stimuli including viral infection. Here, we investigated the role of HIV-1 Tat on the modulation of the Akt/mTORC1 pathway in B cells. We found that HIV-1 Tat activated the Akt/mTORC1 signaling pathway; this leads to aberrant activation of activation-induced cytidine deaminase (AICDA) due to inhibition of the AICDA transcriptional repressors c-Myb and E2F8. These perturbations may ultimately lead to an increased genomic instability and proliferation that might cause B cell malignancies.

Entities:  

Keywords:  AICDA; Akt/mTORC1 pathway; B cells; HIV-1; Tat

Mesh:

Substances:

Year:  2021        PMID: 33557396      PMCID: PMC7915967          DOI: 10.3390/ijms22041588

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  54 in total

1.  The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes.

Authors:  Honyin Chiu; Leandra V Jackson; Kwon Ik Oh; Annie Mai; Ze'ev A Ronai; Davide Ruggero; David A Fruman
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

2.  Hyperactivation of mammalian target of rapamycin complex 1 by HIV-1 is necessary for virion production and latent viral reactivation.

Authors:  Binod Kumar; Sakshi Arora; Shaista Ahmed; Akhil C Banerjea
Journal:  FASEB J       Date:  2016-10-04       Impact factor: 5.191

Review 3.  Evolving epidemiology of HIV-associated malignancies.

Authors:  Meredith S Shiels; Eric A Engels
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

4.  B cell-specific deficiencies in mTOR limit humoral immune responses.

Authors:  Shuling Zhang; Margaret Pruitt; Dena Tran; Wendy Du Bois; Ke Zhang; Rushi Patel; Shelley Hoover; R Mark Simpson; John Simmons; Joy Gary; Clifford M Snapper; Rafael Casellas; Beverly A Mock
Journal:  J Immunol       Date:  2013-07-15       Impact factor: 5.422

5.  mTOR has distinct functions in generating versus sustaining humoral immunity.

Authors:  Derek D Jones; Brian T Gaudette; Joel R Wilmore; Irene Chernova; Alexandra Bortnick; Brendan M Weiss; David Allman
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

6.  HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood.

Authors:  Fatimata Bintou Sall; Rawan El Amine; Diana Markozashvili; Tatyana Tsfasman; Eric Oksenhendler; Marc Lipinski; Yegor Vassetzky; Diego Germini
Journal:  J Cell Physiol       Date:  2019-01-31       Impact factor: 6.384

7.  Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Authors:  Mouna El-Salem; Puthiyaveettil N Raghunath; Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Erle Robertson; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

Review 8.  mTORC1 and mTORC2 as regulators of cell metabolism in immunity.

Authors:  Monika Linke; Stephanie Deborah Fritsch; Nyamdelger Sukhbaatar; Markus Hengstschläger; Thomas Weichhart
Journal:  FEBS Lett       Date:  2017-06-23       Impact factor: 4.124

Review 9.  Adapting the Stress Response: Viral Subversion of the mTOR Signaling Pathway.

Authors:  Valerie Le Sage; Alessandro Cinti; Raquel Amorim; Andrew J Mouland
Journal:  Viruses       Date:  2016-05-24       Impact factor: 5.048

10.  Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan.

Authors:  Takeshi Nishijima; Yosuke Inaba; Yohei Kawasaki; Kunihisa Tsukada; Katsuji Teruya; Yoshimi Kikuchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  AIDS       Date:  2020-05-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.